BJS Academy>Randomized clinical ...>Aspirin vs placebo a...
Normal View Dyslexic View
Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.
16 August 2024
Randomized clinical trials Breast
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.
JAMA 2024; 331: 1714-1721.
Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).
Comment: Theoretical advantage not proven.
BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct275
Randomized clinical trials
Randomized clinical trials
Breast
Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.
16082024
JAMA 2024; 331: 1714-1721.
Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).
